We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 12, 2020

Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

The Lancet Haematology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab for Transplantation-Eligible Patients With Newly Diagnosed Multiple Myeloma (CASSIOPEIA): Health-Related Quality of Life Outcomes of a Randomised, Open-Label, Phase 3 Trial
Lancet Haematol 2020 Dec 01;7(12)e874-e883, M Roussel, P Moreau, B Hebraud, K Laribi, A Jaccard, M Dib, B Slama, V Dorvaux, B Royer, L Frenzel, S Zweegman, SK Klein, A Broijl, KS Jie, J Wang, V Vanquickelberghe, C de Boer, T Kampfenkel, KS Gries, J Fastenau, P Sonneveld

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading